(NASDAQ: COGT) Cogent Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Cogent Biosciences's earnings in 2025 is -$294,372,000.On average, 14 Wall Street analysts forecast COGT's earnings for 2025 to be -$326,355,480, with the lowest COGT earnings forecast at -$344,636,626, and the highest COGT earnings forecast at -$293,010,897. On average, 13 Wall Street analysts forecast COGT's earnings for 2026 to be -$253,273,607, with the lowest COGT earnings forecast at -$311,149,666, and the highest COGT earnings forecast at -$131,555,913.
In 2027, COGT is forecast to generate -$65,721,006 in earnings, with the lowest earnings forecast at -$195,340,598 and the highest earnings forecast at $336,364,550.